100
Participants
Start Date
May 21, 2019
Primary Completion Date
March 30, 2024
Study Completion Date
March 30, 2024
Cladribine
Participants received cladribine tablets as per investigator discretion and as per United States approved label: 3.5 milligram/kilogram (mg/kg) body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
Neurological Associates, Richmond
Sentara Ambulatory Care Center, Virginia Beach
Blacksburg Neurology, PC, Christiansburg
Guilford Neurologic Associates, Greensboro
Fort Wayne Neurological Center, Fort Wayne
Henry Ford Health System, Detroit
Memorial Healthcare, Owosso
Minneapolis Clinic of Neurology - Neurology, Minneapolis
Prairie Education & Research, Springfield
College Park Family Care Center, Overland Park
University of Arkansas for Medical Sciences, Little Rock
Neurology Center of San Antonio, San Antonio
HCA Research Institute, Englewood
Advanced Neurosciences Research, Fort Collins
MS Center of Evergreen, Kirkland
The Elliot Lewis Center for Multiple Sclerosis Care, LLC, Wellesley
UMASS - Neurology, Worcester
VCU Medical Center - Pediatric Neurology, Richmond
Merck KGaA, Darmstadt, Germany
INDUSTRY
EMD Serono Research & Development Institute, Inc.
INDUSTRY